OTLK Outlook Pharma: Enterprise Value to EBITDA Ratio

Outlook Pharma - graphic logo of issuer OTLK

International logistics challenges and patent disputes are impacting raw material supplies for Outlook Therapeutics (OTLK), while the daily price action on GURU.Markets based on the EV/EBITDA metric stands at 0.00. Outlook Therapeutics (OTLK) is implementing automated data analysis and laboratory robotics to accelerate drug development. This ophthalmology innovator aims to make the fight against age-related blindness more accessible, strengthening its authority among physicians.

Outlook Pharma - OTLK Company Value to EBITDA (period 11/23/2025 - 11/13/2026)

OTLK (outlooktherapeutics.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Outlook Pharma|OTLK - Average Forecast Price
- company stock capitalization data:
Market Valuation Outlook Therapeutics Corp|OTLK - Total Enterprise Value
- business book valuation details:
Book Value per Share Outlook Therapeutics|OTLK - Total Stockholders' Equity|Market Value to Book Value Ratio outlooktherapeutics.com|OTLK - Company Total Asset Base
- debt and liquidity data:
Debt to Equity Outlook Therapeutics|OTLK - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Outlook Therapeutics, Inc.|OTLK - Company Aggregate Debts|Debt to Book Value Outlook Therapeutics Corp|OTLK - Amount of Long-Term Liabilities|Company Short-Term Debt Outlook Therapeutics|Quick Liquidity outlooktherapeutics.com
- financial results and valuation multiples details:
OTLK - Company Net Income|Expected Profit Outlook Therapeutics|OTLK - Market Cap to Earnings|Future Price to Earnings Outlook Therapeutics|OTLK - PEG Multiple|Enterprise Value to EBITDA Ratio Outlook Therapeutics Corp|OTLK - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Outlook Therapeutics|OTLK - Earnings per share for the last four quarters|Quarterly EPS earnings growth outlooktherapeutics.com|OTLK - Earnings per share increase in current year|Earnings growth forecast for next year Outlook Therapeutics
Fundamental company analysis:Outlook Pharma (OTLK)
Original product of Outlook Therapeutics Inc

The EV/EBITDA multiple compares the total enterprise value, including debt, with its operating profit before taxes and amortization, determining the real value of the business relative to its ability to generate cash flow. By analyzing fluctuations in the EV/EBITDA multiple, an investor can assess the resilience of Outlook Therapeutics (OTLK) during the market launch of certified bevacizumab and its expansion against non-licensed analogs.

Competing companies

EV/EBITDA Multiple ALC (Alcon Vision)|Bausch Health (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA apellis.com|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Ocular Therapeutix Inc (OCUL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harrow Health|Viridian Corp (VRDN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LENZ Therapeutics, Inc. (LENZ)|OCS - Company Value to EBITDA|EyePoint Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Kodiak Sciences Inc KOD|ALDX: Enterprise Value to EBITDA Ratio|KALA BIO, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|opusgtx.com (IRD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OKYO (OKYO Pharma) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adverum Biotechnologies Inc.|Company Value to EBITDA Clearside Biomedical Inc CLSD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NovaBay Pharmaceuticals (NBY)|KPRX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alimera Sciences, Inc. ALIM|EV/EBITDA Multiple Eyenovia Inc. EYEN|GHSI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation OCUP (Ocuphire Pharma Inc)|OPT (Opthea Ltd.) - Enterprise Value to EBITDA Ratio